The Florida ASCENT Study
Launched by UNIVERSITY OF FLORIDA · Jun 26, 2025
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The Florida ASCENT Study is a research trial designed to help cancer patients improve their access to healthy food and support better eating habits. The study is testing a special program called MyCarePulse combined with the ASCENT patient navigator, whose job is to guide patients through challenges related to food security and nutrition during cancer treatment. Researchers want to see if this program can help patients feel more confident about making healthy food choices, improve the quality of their diet, and reduce difficulties in getting enough nutritious food compared to usual care. They will also check if healthcare providers find this program practical and helpful in supporting patients’ overall wellness.
Adults diagnosed with certain types of cancer—such as colorectal, prostate, lung, breast, gynecologic, blood-related, skin cancers, or melanoma—within the past year may be eligible to join if they live in Florida and can read and speak English or Spanish. Participants will complete questionnaires about their food security, health, and diet, undergo a simple test to measure fruit and vegetable intake, and take part in interviews. In later stages, patients will meet with the ASCENT patient navigator for screenings and consultations to receive personalized support. The study is not yet recruiting but aims to offer useful tools to improve nutrition and care for people living with cancer.
Gender
ALL
Eligibility criteria
- Patient Eligibility Inclusion Criteria:
- • 1. ≥18 years old.
- • 2. Pathologically confirmed diagnosis of colorectal, prostate, lung, breast, gynecologic, hematologic, or skin (including melanoma) cancer within the past 12 months.
- • 3. Self-reported ability to read and speak English.
- • 4. Able to provide informed consent.
- • 5. Participant must not be considered a "vulnerable population" (pregnant women, neonates, children etc.)
- Patient Eligibility Exclusion Criteria:
- • 1. ≤18 years old.
- • 2. Participant do not have a pathologically confirmed diagnosis of colorectal, prostate, lung, breast, gynecologic, hematologic, or skin (including melanoma) cancer within the past 12 months.
- • 3. Participant does not live within the state of Florida.
- • 3) Does not self-reported ability to read and speak English or Spanish. 4) Not able to provide informed consent. 5) Participant is considered a "vulnerable population" (pregnant women, neonates, children etc.)
- • Provider Eligibility Inclusion Criteria
- • 1. ≥18 years old.
- • 2. Currently works as a physician, physician assistant, patient navigator and/or health system/administrative leader in UF and UM affiliated clinics.
- • 3. Self-reported ability to read and speak English or Spanish.
- • 4. Able to provide informed consent.
- • 5. Participant must not be considered a "vulnerable population" (pregnant women, neonates, children etc.)
- • Provider Eligibility Exclusion Criteria
- • 1. ≤ 18 years old.
- • 2. Does not currently works as a physician, physician assistant, patient navigator and/or health system/administrative leader in UF and UM affiliated clinics.
- • 3. Does not self-report having the ability to read and speak English.
- • 4. Not able to provide informed consent.
- • 5. Participant is considered a "vulnerable population" (pregnant women, neonates, children etc.)
About University Of Florida
The University of Florida, a leading research institution, is dedicated to advancing healthcare through innovative clinical trials. With a focus on enhancing patient outcomes and exploring new therapeutic avenues, the university leverages its extensive resources, interdisciplinary expertise, and state-of-the-art facilities to conduct rigorous research across a variety of medical fields. Committed to ethical standards and patient safety, the University of Florida fosters collaboration among researchers, healthcare professionals, and community stakeholders to translate scientific discoveries into impactful clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported